Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation

NCT03969888 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03969888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03969888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
December 11, 2019
Completion date
June 9, 2022
Enrollment
78 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis